Benitec Biopharma Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Benitec Biopharma reported FY2026 results (year ended June 30, 2026) with net loss of $45.5M ($0.98/share) versus $37.9M ($1.05/share) prior year. R&D expenses rose to $23.4M from $18.3M; G&A to $27.8M from $23.4M. Clinical milestone: all six Cohort 1 (low-dose BB-301) patients completed 12-month follow-up; Cohort 2 (high-dose, 3 patients) fully enrolled and dosed. FDA Type C meeting held 3Q2026 on pivotal trial design; interim results to present at ESGCT October 2026; pivotal trial initiation planned mid-2027. Cash position: $180M as of June 30, 2026 (up from $97.7M prior year).
Why this rating
Clinical progress de-risks lead program; strong cash runway (>3.5 years at burn rate) supports mid-2027 pivot trial. Moderate significance: positive clinical data + FDA engagement favorable, but early-stage, orphan indication, single asset. Relative to $153M market cap, $180M cash is substantial cushion; $45.5M annual burn manageable.
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.